# EDGAR Filing Document

**Accession Number:** 0001815903
**File Stem:** 0001104659-25-108552
**Filing Date:** 2025-11
**Character Count:** 5259
**Document Hash:** 81b0c10fafbe3b0648778eaaea8875c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-108552.hdr.sgml**: 20251107

**ACCESSION NUMBER**: 0001104659-25-108552

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251103

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**FILED AS OF DATE**: 20251107

**DATE AS OF CHANGE**: 20251107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Petros Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001815903
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 851410058
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39752
- **FILM NUMBER:** 251463445

**BUSINESS ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 973-242-0005

**MAIL ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 3, 2025**

**Petros Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Delaware**<br> (State or other<br> jurisdiction of<br> incorporation) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **001-39752**<br> (Commission<br> File Number) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **85-1410058**<br> (I.R.S. Employer<br> Identification No.) |

---

**1185 Avenue of the Americas, 3rd Floor**

**New York, New York 10036** (Address of principal executive offices) (Zip code)

**(973) 242-0005** (Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on <br> which registered** |
| Common Stock, par value $0.0001 per share | PTPI | The OTCID Basic Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On November 3, 2025, the Nasdaq Stock Market ("Nasdaq") notified Petros Pharmaceuticals, Inc. (the "Company") that on November 7, 2025, it intended to announce the delisting of the Company's common stock, par value $0.0001 (the "Common Stock"). The Common Stock was suspended from trading on The Nasdaq Capital Market on May 22, 2025, and has been trading on the OTCID® Basic Market (the "OTCID") under the symbol "PTPI" since July 1, 2025. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting in accordance with Rule 12d2-2 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which will deregister the Company's Common Stock under Section 12(b) of the Exchange Act. The delisting will become effective ten days after the Form 25 is filed. The Common Stock will continue trading on the OTCID without disruption and the Company will remain subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Petros pharmaceuticals, Inc** **.** | **Petros pharmaceuticals, Inc** **.** |
| Date: November 7, 2025 | By: | */s/ Fady Boctor* |
|  | Name: | Fady Boctor |
|  | Title: | President and Chief Commercial Officer |

---